Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Don Gibbons Jr., MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Baylor College of MedicineResidency, Internal Medicine, 2004 - 2006
Albert Einstein College of MedicineClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2007 - 2026
OK State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsReceptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.Yang Xia, Kaiwen Wang, Jing Zhao, Zhaohui Arter, Yongchang Zhang
Journal of Thoracic Oncology. 2025-04-01 - 2 citationsImpact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial.Marcelo V Negrao, Alvaro G Paula, David Molkentine, Laura Hover, Monique Nilsson
Clinical Cancer Research. 2025-03-17 - 10 citationsA Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve-Mutant Metastatic Non-Small Cell Lung...Xiuning Le, Jyoti D Patel, Elaine Shum, Christina Baik, Rachel E Sanborn
Journal of Clinical Oncology. 2025-02-01
Press Mentions
MD Anderson Research Highlights: SITC 2024 Special EditionNovember 9th, 2024- MD Anderson Research Highlights for August 11, 2021August 11th, 2021
Meet 2019 STAT Wunderkind Limo Chen, Ph.D., of MD Anderson Cancer CenterJanuary 8th, 2020- Join now to see all
Grant Support
- The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung CancerUNIVERSITY OF TX MD ANDERSON CAN CTR2018–2024
